Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

about

Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.

P2860

Q41169427-6043165E-D0A8-4E44-ACE6-D30BD71F4F3A

P2860

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

Item

http://www.wikidata.org/entity/Q38088002

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

@en

type

Item

label

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

@en

prefLabel

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

@en

P1476

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

@en

P2093

Alden A Moccia

http://www.w3.org/2001/XMLSchema#string

Michele Ghielmini

http://www.w3.org/2001/XMLSchema#string

Zhi-Ming Li

http://www.w3.org/2001/XMLSchema#string

P2860

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

The TOR pathway: a target for cancer therapy

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

P304

313-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.13.6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23477518

http://www.w3.org/2001/XMLSchema#string

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

about

P2860

P2860

Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698